What did @cgo_of_me actually say?
A self-described health coach with 80 pounds of personal weight loss experience laid out a list of things she wished she'd known before starting Ozempic or Mounjaro. The claims span side effect timelines, injection site variability, appetite suppression fading at six months, and average weight loss percentages by drug.
Key specifics: she said it takes four weeks for the medication to reach full effect, that "the first week is definitely the worst," that most people don't feel meaningful appetite suppression until hitting 1 mg on semaglutide or 7.5 mg on tirzepatide, and that after roughly six months at any given dose "most of your side effects wear off including appetite suppression." She also cited 16% average body weight loss for Ozempic and 20% for Mounjaro, with a caveat for people with elevated A1C.
She framed the entire video as non-medical advice and entertainment. That disclaimer matters, but 23,000 views means real people are making real decisions based on this content.
Does the science back this up?
Partially, yes. The weight loss figures are roughly accurate, and the general arc of side effects easing over time is supported by trial data. But some of the mechanistic claims are oversimplified or lack any clinical basis.
The STEP 1 trial (Wilding et al., 2021, NEJM) found semaglutide 2.4 mg produced approximately 14.9% body weight reduction over 68 weeks in non-diabetic adults, not quite the 16% cited, though trial populations vary. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at the highest dose (15 mg) produced up to 20.9% weight loss, so the 20% figure for Mounjaro has support at max dose, but lower doses perform more modestly. Her diabetic A1C caveat is also well-supported. The STEP 2 trial (Davies et al., 2021, Lancet) showed semaglutide produced roughly 9.6% weight loss in people with type 2 diabetes, meaningfully less than in non-diabetic cohorts.
The claim about "four weeks to build up" reflects the pharmacokinetics of semaglutide's half-life of about one week, so steady state is reached around four to five weeks. That checks out.
What did they get wrong (or right)?
The injection site claim is where things get shaky. She says "different injection sites can give you different effects regardless of what people say." There is no peer-reviewed clinical evidence that rotating between the abdomen, thigh, and upper arm produces meaningfully different systemic drug effects. Absorption rates show minor variation, but no published data supports the idea that one site causes worse nausea than another. This reads like anecdote dressed up as advice.
The six-month appetite suppression fade claim is more nuanced than she presented. There is evidence of partial tachyphylaxis to GI side effects over time, but appetite suppression does not simply "wear off" at six months. The STEP trials ran 68 weeks and showed sustained weight loss through that period, which would not happen if hunger suppression vanished at month six. She may be conflating GI side effects (nausea, vomiting) easing with the entire mechanism fading, which are not the same thing.
The practical advice to stay at the lowest effective dose, and to build nutrition habits alongside the medication, is genuinely sound and consistent with clinical guidance from obesity medicine specialists.
What should you actually know?
The side effect timeline framing is useful but imprecise. GI adverse events are most common in the first weeks of a new dose, not necessarily the first week of the entire treatment course. Every dose escalation can reset that discomfort window, which she didn't address.
Her weight loss numbers apply to specific trial populations under controlled conditions. Real-world outcomes vary based on starting weight, comorbidities, adherence, and dose achieved. A 2023 real-world analysis (Wharton et al., Obesity) found mean weight loss in clinical practice settings running modestly below trial figures.
The point about diet and habits mattering as side effects ease is arguably the most clinically important thing she said, and it tends to get buried in GLP-1 content. These medications are not indefinitely self-sustaining. Building behavioral infrastructure while appetite suppression is active is the difference between durable results and rebound weight gain after discontinuation. Research by Wilding et al. (2022, Diabetes, Obesity and Metabolism) showed significant weight regain within a year of stopping semaglutide without lifestyle intervention maintenance.
- GI side effects typically ease with time at a stable dose, but each new dose escalation can bring them back.
- Appetite suppression does not simply stop at six months. Trial data shows continued effect beyond that window at stable doses.
- Weight loss averages from trials reflect best-case, protocol-adherent conditions, not guaranteed individual outcomes.
- Injection site rotation has a practical purpose for skin health, but claims of dramatically different systemic effects by site are not clinically established.